Main efficacy and precautions of neratinib maleate tablets

2024-01-16


It is indicated for adult patients with human epidermal growth factor receptor 2(HER2)-positive early-stage breast cancer after intensive adjuvant therapy with trastuzumab.
Loperamide was given during the first dose of neratinib maleate and the first two subsequent treatment cycles (56 days), and the patient was instructed to maintain 1-2 bowel movements per day and medication to fight diarrhea. Women of childbearing age take effective contraceptive measures during treatment and for at least 1 month after the last dose. Pregnant women are forbidden. Lactating women taking neratinib should not breastfeed until at least 1 month after the last dose.